Fact-checked by Grok 2 weeks ago

Parotidectomy

Parotidectomy is a surgical procedure that involves the partial or complete removal of the , the largest located in front of the and below the , typically performed to excise tumors, alleviate chronic infections, or address other gland pathologies while aiming to preserve the nearby . The produces to aid and oral , and its superficial and deep lobes envelop branches of the , which controls facial expressions, making surgical precision essential to minimize complications. Indications for parotidectomy most commonly include benign neoplasms, most commonly pleomorphic adenomas (accounting for 50-70% of parotid tumors) and Warthin's tumors, as well as malignant tumors, chronic , recurrent , or salivary stones causing obstruction. Less frequent reasons encompass inflammatory conditions like or congenital malformations, though surgery is avoided for non-neoplastic issues such as HIV-related cysts unless necessary. The modern parotidectomy technique was developed in the early ; in 1907, C. A. Cardewine performed the first recorded procedure with facial nerve preservation, and in 1912, Vilray introduced the standard Blair incision for exposing the while protecting the nerve. Types of parotidectomy vary based on tumor location and extent, including superficial (removing the lobe above the ), total (both lobes), partial or extracapsular (for small benign lesions), and radical (sacrificing the nerve for advanced malignancies). The procedure is performed under general by otolaryngologists or head and neck surgeons to achieve oncologic control while preserving function. Detailed surgical techniques, evaluation, risks, and recovery are discussed in subsequent sections.

Introduction

Definition and Indications

Parotidectomy is the surgical excision of part or all of the , the largest of the major , which is located in the preauricular region anterior to the ear and external auditory canal. This procedure involves careful dissection to address pathology within the gland while minimizing damage to surrounding structures. The primary indications for parotidectomy are neoplasms, which constitute the majority of cases, including benign tumors such as and , as well as malignant tumors like and . Parotid tumors account for approximately 80% of all salivary gland neoplasms, with about 80% of parotid neoplasms being benign. In cases, the surgery is typically performed with curative intent for localized disease to achieve complete resection, whereas in advanced or metastatic scenarios, it may serve a palliative role to control symptoms and improve quality of life. Additional indications include chronic inflammatory conditions, such as recurrent or chronic unresponsive to medical management, and that fails conservative measures or less invasive interventions like sialendoscopy. Preservation of the , which traverses the gland, is a critical aspect of the procedure to avoid postoperative complications.

Historical Development

The first documented description of parotidectomy appeared in 1765, when German surgeon Lorenz Heister detailed the procedure in his surgical text, highlighting the challenges posed by the gland's rich vascular supply from branches of the , which complicated and increased operative risks. Early parotidectomies, often performed without or modern sterile techniques, were fraught with high mortality rates, primarily due to severe postoperative infections and inevitable facial nerve damage resulting in permanent and functional impairment. These initial efforts laid the groundwork for surgery but underscored the procedure's dangers in an era before antisepsis and anatomical precision. The brought pivotal advancements that transformed surgical outcomes. In 1825, Johann Ferdinand Heyfelder of pioneered techniques for preservation during parotid resection, marking a shift toward less destructive approaches for tumor removal. The introduction of principles by in 1867, through the use of carbolic acid to combat wound infections, dramatically reduced postoperative rates across surgical fields, including parotidectomy, thereby lowering overall mortality and enabling safer gland excisions. By 1892, Romanian surgeon M. Codreanu achieved the first total parotidectomy with successful preservation under general , further establishing the feasibility of nerve-sparing operations. In the early , refinements in identification and surgical access revolutionized parotidectomy. English surgeon Thomas Carwardine advocated in 1907 for systematically locating the trunk prior to tumor , reducing inadvertent injury risks. Vilray P. Blair introduced the classic cervicomastoidfacial (Blair) incision in 1912, which provided superior exposure of the parotid region while minimizing cosmetic deformity, and it became the standard approach popularized throughout the . Mid-century contributions from key figures such as William E. Sistrunk, who in 1921 described en bloc superficial parotidectomy to lower recurrence rates for benign tumors, and Hayes Martin, who in 1952 outlined detailed antegrade nerve techniques, solidified modern superficial parotidectomy as the preferred method for preserving facial function. The late ushered in technological innovations that enhanced precision and safety. Since the , computed , first applied to the with contrast sialography in 1979, has allowed for detailed preoperative mapping of tumors relative to the and adjacent structures, improving surgical planning. Intraoperative emerged in the 1980s, with pioneers like Jack Kartush modifying devices in 1980 to provide real-time auditory and visual feedback on nerve integrity, significantly decreasing permanent rates. In parallel, minimally invasive techniques, including extracapsular for benign lesions, gained traction from the late 1980s onward, offering reduced morbidity while maintaining oncologic .

Anatomy of the Parotid Region

Parotid Gland Structure

The is the largest of the major salivary glands, weighing approximately 25 grams in adults and situated in the retromandibular fossa. It is positioned anterior to the external auditory canal and extends from the anterior border of the to the posterior border of the , with superior extension to the and inferior extension below the angle of the . This location places it superficial to the mandible's ramus and deep to the skin and , making it palpable over the lateral aspect of the below the . The gland is divided into a superficial lobe and a deep lobe by the extratemporal and the posterior facial vein, with the superficial lobe comprising approximately 80% of the total parotid tissue volume. The superficial lobe lies lateral to the and overlies the and mandibular ramus, while the deep lobe is medial to the nerve and positioned between the mastoid process and the ascending ramus of the . Enclosing the entire gland is a thin fibrous capsule, known as the parotid sheath, derived from the deep cervical fascia, which provides structural support and defines surgical boundaries. The lobes are connected by tissue containing fatty elements, and the gland's lobular architecture is formed by that convey neurovascular structures. Histologically, the parotid gland is a purely serous acinar gland composed primarily of serous acini that secrete watery saliva rich in amylase for initial starch digestion. These acini are clusters of pyramidal serous cells surrounded by myoepithelial cells that contract to aid saliva expulsion, embedded within a supportive stroma of extracellular matrix, fibroblasts, immune cells, and nerves. The ductal system begins with intercalated ducts draining the acini, progressing to striated ducts for ion reabsorption, and culminating in excretory ducts; the main excretory duct, Stensen's duct, arises from the anterior aspect of the superficial lobe, courses over the masseter muscle for about 7 cm, pierces the buccinator muscle, and opens into the oral cavity opposite the upper second molar tooth. Arterial blood supply to the derives from branches of the , primarily the and its transverse facial branch, along with contributions from the . Venous drainage occurs via the retromandibular vein, which forms from the of the superficial temporal and maxillary veins within the gland and descends to join the . Lymphatic drainage is unique among salivary glands, featuring intraparotid lymph nodes embedded within the superficial lobe and capsule that serve as the first echelon for lymphatic spread from the , face, external auditory canal, and certain head and malignancies. These nodes ultimately drain into the superficial and chains.

Facial Nerve and Adjacent Structures

The , or cranial nerve VII, follows an extratemporal course after emerging from the stylomastoid , entering the approximately 1-2 cm inferior to the external auditory , where it divides into the temporofacial and cervicofacial trunks. These trunks further branch into the five main peripheral branches—temporal, zygomatic, buccal, marginal mandibular, and —which fan out through the gland to innervate the muscles of facial expression. This branching occurs within the parotid substance, separating the superficial and deep lobes, and the nerve's arborization pattern is crucial for preserving facial function during surgical dissection. Surgical identification of the facial nerve relies on consistent anatomical landmarks to minimize injury risk. The tragal pointer, a cartilaginous prominence at the tragus base, lies approximately 1.6 cm anterior and deep to the main trunk. The tympanomastoid suture, located posterior to the external auditory canal, marks the nerve about 3-4 mm deep and inferior along its line. Additionally, the posterior belly of the serves as a reliable inferior , with the nerve trunk positioned superficial and slightly anterior to it at a mean distance of 5.5 mm. Adjacent structures to the influence surgical approaches and potential complications. Anteriorly, the gland overlays the , while superiorly it abuts the external auditory canal and . Inferiorly, it extends to the mandible's angle, and the deep lobe wraps around the styloid process, lying in close proximity to the and medially. Anatomical variations in the occur, including early high branching, trunk duplication, or atypical arborization patterns such as the "anomalous temporozygomatic ." These anomalies, often classified by systems like or Kopuz, underscore the need for preoperative imaging to map individual . The provides motor innervation to the muscles of via its terminal es, enabling movements like eye closure and smiling. Parasympathetic secretomotor fibers to the originate from the (cranial nerve IX) and are relayed through the to the , with postganglionic fibers traveling via the (a trigeminal ) to stimulate serous production.

Diagnosis and Assessment

Clinical Presentation

Patients with pathology often present with a painless swelling or mass in the parotid region, which is the most frequent initial symptom prompting evaluation. This swelling typically develops gradually and may cause facial asymmetry due to the on surrounding tissues. In cases of or , may accompany the swelling, distinguishing it from the more common benign presentations. Additional symptoms can include difficulty , numbness, or in the face if the mass affects adjacent structures. On , the mass is often mobile and well-defined in benign conditions, whereas fixation to surrounding tissues suggests . involvement, such as or ulceration, is a of advanced malignant , while facial nerve invasion may manifest as weakness or on the affected side. In inflammatory processes like , the gland may appear erythematous and tender, mimicking with ear pain and swelling near the auricle. Associated features vary by ; chronic can lead to due to reduced salivary flow from glandular obstruction or inflammation. hinges on growth characteristics: slow, indolent progression favors benign tumors like , whereas rapid enlargement points to . Parotid pathologies leading to surgical consideration are more prevalent in adults over 50 years of age, with a diagnosis around 56-64 years. Certain subtypes, such as , exhibit a slight male predominance.

Diagnostic Investigations

Diagnostic investigations for primarily involve and techniques to confirm the nature of , assess extent, and guide surgical planning. serves as the initial modality, providing real-time assessment of lesion size, location, and vascularity, with high sensitivity for detecting superficial parotid masses. Computed tomography () is utilized when bony involvement or deeper extension is suspected, offering detailed evaluation of skull base erosion or adjacent structures. () is the preferred modality for characterization and assessment, employing T1-weighted sequences for anatomical detail and T2-weighted sequences to highlight cystic components or perineural spread. Biopsy techniques are essential for histopathological confirmation. Fine-needle aspiration (FNA) cytology is the standard initial procedure, demonstrating approximately 96% accuracy (AUSROC 0.96) in distinguishing malignant from benign parotid lesions, though it may yield nondiagnostic results in up to 20% of cases. Results are typically reported using the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC), a standardized framework that categorizes findings into six risk levels to guide management. Core needle biopsy is recommended if FNA is inconclusive, providing more tissue for analysis with improved diagnostic yield. Intraoperatively, frozen section analysis can be performed during parotidectomy to guide the extent of resection, particularly in cases of suspected malignancy. For malignant parotid tumors, follows the American Joint Committee on Cancer (AJCC) TNM system, which incorporates findings to evaluate size (T), regional nodal involvement (N), and distant (M), with MRI and crucial for assessing extraglandular extension and status. Adjunctive tests address specific etiologies. Sialography, involving contrast injection into the , is used to identify ductal stones (sialoliths) and obstructions, revealing filling defects or dilatations with high diagnostic accuracy. In suspected high-grade malignancies, positron emission tomography-computed tomography (PET-CT) aids metastatic workup by detecting occult nodal or distant disease, improving accuracy over conventional alone. Preoperative evaluation of facial nerve function includes (EMG) in patients with baseline weakness, quantifying nerve impairment and predicting postoperative outcomes to inform surgical approach.

Surgical Procedure

Types of Parotidectomy

Parotidectomy procedures are classified based on the extent of glandular resection, which is determined by the tumor's characteristics to balance oncologic control with preservation of function and surrounding structures. The primary types include superficial, total, radical, and partial or limited approaches, with superficial parotidectomy being the most common, accounting for the majority of cases involving benign neoplasms that constitute 75-80% of parotid tumors. Superficial parotidectomy involves the removal of the superficial lobe of the while identifying and preserving the main trunk and branches of the . This approach is indicated for tumors confined to the superficial lobe, such as most benign lesions including pleomorphic adenomas and Warthin tumors. It represents 70-80% of parotidectomies due to the prevalence of superficially located benign pathology. Total parotidectomy entails excision of both the superficial and deep lobes with preservation of the , often requiring mobilization of nerve branches to access deep extensions. It is performed for tumors involving the deep lobe, multifocal disease, or large neoplasms where lobe distinction is unclear, particularly in cases of aggressive benign or low-grade malignant tumors. Radical parotidectomy includes total gland removal along with sacrifice of the and potential resection of adjacent skin, muscle, or bone if malignancy invades these structures. This is reserved for advanced malignant tumors with preoperative or circumferential involvement, prioritizing oncologic clearance over function. Partial or limited parotidectomy, encompassing techniques like enucleation or extracapsular , removes the tumor with a minimal cuff of surrounding without routine identification of the main trunk, often aided by monitoring. It is considered for small, mobile benign lesions excluding pleomorphic adenomas, though it remains controversial due to higher recurrence risks—up to 45% historically with enucleation—compared to more extensive resections. Selection of the parotidectomy type relies on preoperative (e.g., MRI or ) to assess tumor location relative to the plane, size (with larger tumors >4 cm often necessitating total resection), histological diagnosis via , and evidence of nerve involvement such as or enhancement on . Benign histology favors nerve-preserving approaches, while may escalate to radical if invasion is confirmed.

Preoperative Preparation

Preoperative preparation for parotidectomy involves a thorough multidisciplinary to optimize patient outcomes and minimize surgical risks. A team typically comprising an otolaryngologist-head and neck surgeon, oncologist, radiologist, and pathologist assesses the patient's overall health, tumor characteristics, and potential for involvement based on prior diagnostic imaging and results. is obtained after detailed discussion of procedure-specific risks, including transient paresis, which occurs in 16.6-34% of cases, with most recovering within weeks to months. Permanent is rarer, affecting less than 1-2% in non-malignant cases. Anesthesia planning emphasizes general anesthesia with endotracheal intubation, often nasotracheal to facilitate surgical access, while avoiding muscle relaxants to preserve facial nerve responsiveness during monitoring. Airway evaluation is critical due to the parotid gland's proximity to pharyngeal structures, with fiberoptic intubation or preoperative tracheostomy considered for patients with deep-lobe tumors or anticipated difficult airways. Prophylactic antibiotics, such as cefazolin, are administered intravenously upon induction to prevent surgical site infections, particularly in clean-contaminated head and neck procedures. Perioperative steroids are not routinely recommended for swelling reduction, as evidence does not support their efficacy in improving facial nerve outcomes or reducing edema in standard parotidectomy cases. Adjunctive measures include setup for intraoperative facial nerve monitoring using electromyography to aid nerve identification and reduce injury risk, which is employed in most centers for both benign and malignant resections. Preoperative marking of the incision line, typically a modified Blair incision extending from preauricular to the cervical crease, ensures optimal cosmetic and functional results while accommodating potential extensions. For tumor-specific preparation, concurrent is planned if preoperative imaging or indicates cervical nodal involvement, particularly in high-grade malignancies involving levels I-III. Malnourished patients, common in advanced head and neck cases with up to 40% prevalence, receive preoperative nutritional support through oral supplements or enteral feeding to improve tolerance and .

Intraoperative Techniques

The intraoperative phase of parotidectomy begins with the patient under general anesthesia, positioned with the head turned away from the surgical side to facilitate access. A modified S-shaped incision is commonly employed, starting in the preauricular crease, curving around the , and extending into the upper skin crease for optimal and exposure. This incision allows elevation of an anterior skin flap in the sub-superficial musculoaponeurotic system (SMAS) plane, extending beyond the tumor margins to expose the parotid capsule while preserving the greater auricular posteriorly when possible. The flap is raised meticulously to maintain its thickness, reducing the risk of postoperative complications such as Frey syndrome. Identification of the is a critical step to preserve its function, typically initiated via an anterograde approach using anatomical landmarks such as the tragal pointer, where the main trunk emerges approximately 1 cm inferior and anterior to this pointer, and the tympanomastoid suture line. If the anterograde method is obscured by tumor involvement, a from peripheral branches may be employed, starting from the uppermost or lowermost branch and tracing proximally. Intraoperative with a stimulator is standard in many centers, delivering low-intensity pulses (e.g., 0.5 mA) to confirm integrity and differentiate motor from sensory fibers, often supplemented by for real-time feedback. magnification (typically 2.5x to 4x) aids in precise , with an operating reserved for intricate branching in complex cases. Resection of the proceeds following nerve delineation, mobilizing the superficial lobe by incising the capsule and ligating vessels with fine ties or cautery to achieve while sparing the branches. For superficial parotidectomy, the lobe is removed en bloc with the tumor and a margin of normal tissue; if deep lobe involvement is present, the is retracted anteriorly to access this portion, reflecting the superficial lobe superiorly or using a transcervical approach for delivery. The specimen is oriented intraoperatively with marking sutures for pathological evaluation to assess margins and involvement. Advanced tools like LigaSure may be used for vessel sealing to expedite and reduce operative time. Closure involves layered suturing of the SMAS and platysma, followed by platysmal approximation over the surgical defect to prevent contour irregularities, with skin edges closed in a tension-free manner using subcuticular sutures. A closed-suction is routinely placed to manage formation, exiting through a separate stab incision and secured. is meticulously ensured throughout with electrocautery to avoid injury to adjacent structures. The procedure typically lasts 2 to 4 hours, depending on tumor complexity and extent of resection.

Postoperative Management

Following parotidectomy, patients are transferred to the post-anesthesia care unit () for initial monitoring of , assessment for bleeding or formation, and evaluation of airway patency to ensure stable recovery from . function is promptly checked by observing the patient's ability to , , and close their eyes, with any immediate weakness noted for ongoing surveillance. is managed with a approach, including intravenous or oral opioids for moderate to severe discomfort and nonsteroidal drugs (NSAIDs) for milder , titrated to patient response while monitoring for side effects such as . Wound care begins in the with sterile dressings applied over the incision site, kept dry for the first 24-48 hours to promote healing and reduce risk. A drain is typically placed during to prevent or accumulation and is managed by emptying and measuring output every 8-12 hours; prophylactic antibiotics are continued postoperatively, often intravenously for 24-48 hours, to minimize surgical site infections. The drain is removed when output falls below 25-30 mL per 24 hours, usually within 1-2 days, after which the incision is monitored for signs of drainage or dehiscence. Facial nerve assessment continues daily through bedside evaluations using standardized scales like the House-Brackmann grading system to detect evolving or . If injury results in (incomplete eyelid closure), immediate eye protection measures are instituted, including lubricating ointments, moisture chamber goggles, or eyelid taping at night to prevent corneal exposure and ulceration. Nutrition is advanced gradually, starting with clear liquids in the to assess swallowing tolerance, progressing to a soft by postoperative day 1 while avoiding acidic or spicy foods that may irritate the surgical site. Early mobilization is encouraged within 24 hours of , with assisted ambulation to reduce the risk of deep vein thrombosis (DVT), often supplemented by sequential compression devices as mechanical prophylaxis. The typical stay lasts 1-3 days, depending on the extent of and factors such as drain output and pain control. Discharge criteria include stable , drain removal or output less than 30 per day, adequate with oral medications, and the ability to tolerate oral intake without complications. Vigilance for early signs of acute complications, such as expanding or , is maintained throughout the inpatient period.

Complications

Acute Complications

Acute complications of parotidectomy encompass short-term risks that typically manifest within days to weeks following surgery and are often reversible with prompt intervention. These include hematoma or seroma formation, infection, facial nerve paresis, salivary leakage leading to sialocele or fistula, and rare instances of airway compromise due to swelling. The vulnerability of the facial nerve, which traverses the parotid gland, contributes to some of these risks during dissection. Hematoma and seroma are among the most common acute issues, occurring in approximately 1-3% of cases, with pooled incidence rates of 2.9% for (95% CI: 2.4-3.5%) from systematic reviews of parotidectomies primarily for benign tumors. These collections of or can cause localized swelling and , potentially expanding the surgical site if not addressed. Management involves prompt surgical evacuation for hematomas to control bleeding sources, while seromas may require or closed to prevent accumulation; prophylactic drains are routinely placed intraoperatively to mitigate risk. Infection rates, including wound infections and salivary fistulas, range from 1-5%, with wound infections at 2.3% (95% CI: 1.8-2.9%) and salivary fistulas at 3.1% (95% CI: 2.6-3.7%) in aggregated data from benign parotid surgeries. Wound infections present as , induration, or purulent discharge, while salivary fistulas involve persistent leakage of through the incision, often linked to incomplete ductal . Treatment typically includes intravenous antibiotics for confirmed infections, with surgical or for abscesses; fistulas may initially respond to conservative measures like pressure dressings before escalating to . antibiotics further reduce incidence in high-risk cases. Facial nerve paresis is a frequent acute concern, with temporary dysfunction reported in 10-30% of benign parotidectomy cases and permanent paresis in 1-5%, based on subsite analyses and multicenter reviews. Temporary paresis, often due to edema, traction, or thermal injury during nerve identification, manifests as partial facial weakness within the first week and usually resolves within 6 months through spontaneous recovery aided by corticosteroids or observation. Permanent cases, rarer in benign tumors, may necessitate nerve grafting if identified intraoperatively, though most acute presentations are managed expectantly with eye protection to prevent corneal exposure. Intraoperative nerve monitoring helps minimize but does not eliminate this risk. Salivary leakage, resulting in sialocele formation, occurs in 2-6% of procedures, typically 7-14 days postoperatively, presenting as a painless fluctuant swelling from accumulated . Sialoceles often resolve spontaneously or with , including serial , dressings, and anticholinergics to reduce production; injection into the achieves 70-100% success in refractory cases by temporarily paralyzing secretory function. Distinction from is key, as sialocele fluid shows high levels. Airway compromise is a rare but serious acute complication, with incidence below 1%, arising from extensive postoperative swelling, hematoma expansion, or sialadenitis that obstructs the upper airway. It may require emergent or reintubation for airway protection, particularly in cases of massive ; close monitoring in a setting with elevation of the head and steroids can prevent progression. Such events are more likely in extensive resections but resolve with supportive care.

Chronic Complications

Chronic complications of parotidectomy encompass delayed or persistent effects that can significantly impact patients' , often emerging months to years post-surgery due to anatomical changes, nerve disruptions, or tumor biology. These sequelae arise from the removal of tissue and associated structures, leading to functional and aesthetic deficits that may require ongoing management. Frey syndrome, also known as gustatory sweating, is a common chronic complication characterized by facial flushing, sweating, and sometimes warmth in the preauricular region during eating, resulting from aberrant regeneration of parasympathetic nerve fibers following disruption of the and overlying skin innervation during surgery. The clinical incidence varies widely, reported from 4% to 96% depending on diagnostic methods, with symptomatic cases affecting approximately 10-50% of patients, though many are mild and self-limiting. Treatment options include topical anticholinergics for mild cases, intradermal injections to inhibit activity (effective for 6-12 months with repeat dosing), or surgical interventions like interposition grafts using or acellular to prevent nerve regrowth in severe, refractory instances. Facial asymmetry and scarring represent aesthetic chronic sequelae from the loss of parotid gland volume, creating a contour defect or "hollowing" in the cheek and preauricular area, which can persist indefinitely and contribute to psychosocial distress. This defect occurs due to the resection of substantial glandular tissue, often exacerbated by postoperative atrophy or scarring from the surgical incision, with visible asymmetry noted in up to 20-30% of cases without reconstructive measures. Management strategies focus on volume restoration and scar revision; techniques include autologous fat transfer for natural filling (with 50-70% graft survival and improved symmetry in long-term follow-up), dermal-fat grafts from the abdomen or thigh to replace lost volume, or alloplastic fillers like hyaluronic acid for temporary correction. In select cases, superficial musculoaponeurotic system (SMAS) flaps or facelift approaches during initial surgery can minimize asymmetry by preserving or repositioning native tissues. First-bite syndrome is a rare but distressing condition involving sharp, cramping pain in the parotid region triggered by the initial bite of a meal, typically resolving with subsequent chews, attributed to sympathetic denervation of the following surgical disruption of the external carotid sympathetic . Incidence is low, estimated at 1-10% after parotidectomy involving deep lobe or dissection, with symptoms often appearing within weeks to months postoperatively and potentially lasting years if untreated. includes dietary modifications (e.g., avoiding acidic foods) and analgesics, while injections into the provide relief by modulating neural activity in 70-80% of cases, with surgical sympathectomy reserved for refractory symptoms. Sensory loss, manifesting as numbness or in the , lower , and , is a frequent chronic outcome from sacrifice or injury to the (GAN), which supplies sensation to these areas and is commonly transected during superficial parotidectomy to access the gland. This leads to permanent or slowly recovering deficits in 40-80% of cases where the GAN is not preserved, with the posterior branch often divided to facilitate tumor exposure, resulting in dysesthesia that peaks at 3-6 months and improves over 1-2 years via collateral nerve sprouting. Preservation of the GAN, when oncologically feasible, can reduce long-term sensory impairment (e.g., 41% at 12 months with preservation versus 76% without in one multicenter study), though residual deficits may still occur and affect . Tumor recurrence, while primarily a disease-related sequela rather than a direct surgical complication, poses a chronic risk following parotidectomy, influenced by surgical margins, tumor , and therapies, with benign tumors like recurring in 1-5% of cases over 5-10 years due to incomplete excision or multifocal growth. For malignant parotid tumors, recurrence rates are higher, ranging from 10-30%, often involving the parotid bed or regional nodes within 2-5 years, necessitating vigilant imaging surveillance to detect and resect early for improved outcomes.

Prognosis and Follow-up

Treatment Outcomes

Parotidectomy for benign tumors, such as pleomorphic adenomas, achieves a cure rate exceeding 95% with superficial parotidectomy, primarily due to the low recurrence rates associated with complete excision while preserving the . Recurrence occurs in only 2-5% of cases following superficial parotidectomy, with meta-analyses confirming rates as low as 0.7-2.4% for partial or superficial approaches in well-selected patients. These outcomes are supported by long-term studies showing 5-year overall survival rates of 100% and locoregional recurrence-free survival of over 92% for benign parotid lesions. For malignant parotid tumors, treatment outcomes vary significantly by histological grade, with 5-year survival rates ranging from 70-90% for low-grade malignancies like and 30-50% for high-grade tumors such as salivary duct carcinoma. Adjuvant following parotidectomy improves local control rates, particularly in high-grade cases with adverse features, achieving locoregional control in up to 92% at 2 years and enhancing overall survival in retrospective analyses. Negative surgical margins, achieved in approximately 80% of cases through adequate resection, are a key prognostic factor, correlating with reduced local recurrence. Functional outcomes after parotidectomy emphasize facial nerve preservation, with over 90% of patients achieving good long-term and function in benign cases, as permanent rates remain below 6%. However, complications such as temporary or can impact quality of life in about 20% of patients, though most recover fully within 6-12 months, leading to sustained satisfaction in the majority. Success is further influenced by tumor stage at diagnosis and intraoperative nerve preservation techniques, which minimize deficits and support favorable cosmetic and functional results. Meta-analyses demonstrate that more extensive resections, such as total parotidectomy versus partial, reduce recurrence rates for certain malignant or multifocal tumors, with total approaches yielding rates as low as 1% compared to 2-4% for limited excisions, without proportionally increasing morbidity. These findings underscore the importance of tailoring surgical extent to while prioritizing oncologic clearance.

Long-term Monitoring

Long-term monitoring after parotidectomy focuses on detecting tumor recurrence, assessing functional recovery, and addressing quality-of-life impacts through structured surveillance protocols, particularly for patients with malignant tumors. According to (NCCN) guidelines, follow-up clinic visits are recommended every 1-3 months in the first year, every 2-6 months in the second year, every 4-8 months during years 3-5, and annually thereafter, extending up to 20 years due to the risk of late recurrences in tumors like . , such as contrast-enhanced MRI or of the primary site and chest , is typically performed every 6-12 months for the first 2 years post-treatment, with subsequent scans guided by symptoms or high-risk features like high-grade . These protocols aim to balance vigilant monitoring with minimizing unnecessary . Assessments during follow-up include comprehensive physical examinations of the head and neck to evaluate for new masses, , or changes in , alongside targeted evaluation of function using scales like the House-Brackmann grading system. Patient-reported outcomes are incorporated to gauge , encompassing symptoms such as dry mouth (), eating difficulties, or emotional distress related to cosmetic alterations. For high-risk cases, may be conducted every 6-12 months if neck radiation was involved, to detect radiation-induced . Recurrence detection relies on vigilance for symptoms such as progressive facial swelling, new lumps in the parotid bed, or neurological deficits like worsening facial weakness, with over 70% of recurrences occurring within the first 3 years. Suspicious findings prompt biopsy or core biopsy for histopathological confirmation, often combined with advanced imaging like PET-CT if is suspected. Rehabilitation for persistent issues includes emphasizing neuromuscular reeducation and facial exercises to improve muscle strength and symmetry in cases of , with evidence supporting protocols like mirror or proprioceptive stimulation for functional recovery. Psychological support is recommended to manage cosmetic concerns and issues, particularly in younger patients or those with visible . NCCN recommendations underscore multidisciplinary surveillance tailored to tumor and , integrating oncologic, rehabilitative, and supportive care to optimize long-term outcomes.

Terminology

Etymology

The term "parotidectomy" combines "parotid," referring to the located near the , with the suffix "-ectomy," denoting surgical removal. The root "parotid" derives from the New Latin "parotis," borrowed from "parōtis," meaning "tumor near the " or " beside the ," formed by "pará" (beside or near) and "ôus" (), highlighting the gland's anatomical position anterior to the . The suffix "-ectomy" originates from the Greek "ektomḗ," a of "ek-" (out) and "tomḗ" (a cutting or incision), signifying the excision of an or , a convention adopted in modern medical during the . The full term "parotidectomy" was coined in the late , with its earliest recorded use in 1893 in a medical dictionary, reflecting the of surgical terminology as procedures became more defined. A related term, "parotitis," describes of the and stems from the Greek "parōtîtis," combining "parōtís" (the ) with "-îtis" (), first appearing in English in 1796.

Surgical Nomenclature

nomenclature encompasses standardized terminology for surgical procedures involving the to ensure clarity in medical reporting and outcomes assessment. Key terms distinguish between conservative and more extensive resections, reflecting the balance between oncologic adequacy and functional preservation. These terms have evolved to address inconsistencies in historical descriptions, promoting uniformity across clinical studies and practice guidelines. Enucleation refers to the simple shelling out of a tumor from the without formal identification or dissection of the , typically reserved for select benign lesions to minimize morbidity. Extracapsular dissection extends beyond enucleation by removing the tumor with a margin of surrounding parotid tissue outside the tumor capsule, still avoiding complete dissection, and is often employed for benign tumors aided by intraoperative nerve monitoring. Nerve-sparing parotidectomy involves meticulous dissection and preservation of the during tumor excision, standard for benign conditions and most malignancies to maintain facial function. In contrast, nerve-sacrificing procedures entail resection of the , indicated in cases of preoperative or advanced invasion, frequently followed by nerve grafting or reconstruction. Incision types in parotidectomy include the classic incision, which follows the preauricular crease, extends around the , and curves into the cervical region for broad access. The retroparotid or facelift incision modifies this by extending posteriorly into the retroauricular crease, prioritizing cosmetic outcomes while providing adequate exposure. Cosmetically modified variants, such as limited or approaches, further adapt these to reduce visible scarring. For pathology-specific nomenclature, in low-grade parotid malignancies, close surgical margins (typically ≤5 mm) are considered adequate in early-stage cases, providing excellent outcomes without compromising , though wider margins may be aimed for to further minimize recurrence risk, especially near critical structures like the . Major guidelines, such as those from ASCO (2021), define close margins as ≤5 mm for low- and intermediate-grade tumors, supporting their use in appropriate cases. Evolving terminology in combined procedures has shifted from "radical neck dissection," which removes multiple lymph node levels and non-lymphatic structures, to "selective neck dissection," targeting specific levels (e.g., II-IV) based on metastasis patterns in parotid cancers for reduced morbidity. Standardization efforts, such as those by the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), emphasize consistent reporting of procedure types (e.g., superficial vs. total) and outcomes like margin status and nerve function to facilitate comparative research. The European Salivary Gland Society proposes limiting terms to "extracapsular dissection" for limited resections and "parotidectomy" for those involving facial nerve dissection and at least one glandular level, subdividing the gland into five levels for precise description. Similarly, revisions by Tweedie and advocate segmenting the gland into upper, middle, and lower portions per lobe to refine classifications beyond superficial/deep dichotomies.

References

  1. [1]
    Parotidectomy - StatPearls - NCBI Bookshelf - NIH
    Parotidectomy is the partial or complete removal of the parotid gland; the procedure may be indicated for various reasons, including inflammatory conditions.
  2. [2]
    Parotidectomy: Procedure & Recovery - Cleveland Clinic
    Parotidectomy is surgery to remove part or all of your parotid gland. The surgery treats tumors and conditions that block your gland.
  3. [3]
    Parotid Gland: Anatomy, Function, Location & Definition
    surgery to remove part or all of your parotid gland. People with parotid gland cancer may need surgery to ...
  4. [4]
    Parotid Gland Tumors: Symptoms, Causes & Treatment
    Mar 11, 2024 · A parotid gland tumor is a rare tumor on one of your salivary glands. Most parotid tumors are benign (noncancerous), but they can be cancerous.
  5. [5]
    Parotid tumors - Diagnosis and treatment - Mayo Clinic
    Feb 21, 2025 · Parotid tumor treatment often involves surgery to remove the tumor. If the tumor is cancerous, you might need more treatment. This could be with radiation ...
  6. [6]
    Parotidectomy: Overview, Periprocedural Care, Preparation
    Sep 3, 2024 · A superficial (or lateral) parotidectomy involves removing all of the gland superficial to the facial nerve, whereas a partial superficial parotidectomy ...Overview · Introduction · Complications
  7. [7]
    Parotid Cancer - StatPearls - NCBI Bookshelf - NIH
    A good rule of thumb to remember is the rule of 80s; that 80% of all salivary tumors are in the parotid, 80% of parotid tumors are benign, and 80% of the ...
  8. [8]
    Extent of Parotid Disease Influences Outcome in Patients With ...
    Three patients, one from each group, were treated with palliative intent only. In summary, 105 of 126 patients had surgical treatment and 93 of these (89%) ...
  9. [9]
    Anatomy, Head and Neck, Parotid Gland - StatPearls - NCBI Bookshelf
    Sep 10, 2024 · Most nodes are located within the superficial lobe between the gland and the parotid capsule.[2] Skin cancers of the face or scalp can ...
  10. [10]
    Selective Deep Lobe Parotidectomy vs Total Parotidectomy for ... - NIH
    Sep 28, 2023 · The superficial lobe accounts for approximately 80% of parotid tissue volume ... Tumor Located in Deep Lobe of Parotid Gland With Superficial Lobe ...Missing: proportion | Show results with:proportion
  11. [11]
    Facial Nerve Anatomy and Clinical Applications - StatPearls - NCBI
    May 23, 2023 · This segment gives off three branches: the nerve to stapedius muscle, the chorda tympani (containing parasympathetic fibers to sublingual and ...
  12. [12]
    Identification of Facial Nerve During Parotidectomy - NIH
    The facial nerve along with the accompanying vessels creates a potential plane which lies in between the deep and superficial lobes of the parotid gland.
  13. [13]
    The Precision of Four Commonly Used Surgical ... - PubMed
    Feb 20, 2010 · The main trunk of the facial nerve was found 5.5+/-2.1mm from the PBDM, 6.9+/-1.8 mm from the TP, 10.9+/-1.7 mm from the EAM and 2.5+/-0.4 mm ...
  14. [14]
    Variations in Facial Nerve Branches and Anatomical Landmarks for ...
    Nov 8, 2019 · The purpose of this study was to evaluate facial nerve (FN) branching variations based on Davis and Kopuz classifications in the Lithuanian population.
  15. [15]
    Intra-parotid Course and Variations in the Branching Pattern of ... - NIH
    The extratemporal part of the facial nerve traverses through the parotid gland and divides into terminal branches. There is variability in the branching ...
  16. [16]
    Anatomy, Head and Neck: Auriculotemporal Nerve - StatPearls - NCBI
    Aug 8, 2023 · The auriculotemporal nerve is a division of the trigeminal nerve with some post otic ganglionic parasympathetic fibers from the ...
  17. [17]
    Parotid Gland Tumors | Johns Hopkins Medicine
    A painless swelling on one side of your face may indicate a mass or tumor on your parotid gland. · Most parotid tumors are benign (not cancerous). · Cancer in the ...
  18. [18]
    Parotid tumors - Symptoms and causes - Mayo Clinic
    Feb 21, 2025 · Learn about symptoms and diagnosis of parotid gland tumors. Find out how operations, such as parotidectomy, can treat parotid tumors and ...
  19. [19]
    Parotitis - StatPearls - NCBI Bookshelf - NIH
    Jun 23, 2025 · Clinically, parotitis is typically painful and presents with unilateral glandular swelling and reduced salivary flow, except in cases associated ...
  20. [20]
    Distribution and Frequency of Salivary Gland Tumours - NIH
    The average age for malignant tumours was 56 years with a female average of 54.4 and male average age of 57.4 years. As for benign tumours, the age range was ...
  21. [21]
    Warthin Tumor - StatPearls - NCBI Bookshelf - NIH
    There is an apparent male predilection for the occurrence of Warthin tumors ... [23] The solid portion is predominant in the Warthin tumors, and small ...
  22. [22]
    Cross-sectional Imaging of Parotid Gland Nodules: A Brief Practical ...
    The aim of this work is to provide the radiologist some fundamental clues while evaluating parotid lesions on CT scan or MR imaging (MRI), starting from the ...
  23. [23]
    Imaging Evaluation of Pediatric Parotid Gland Abnormalities
    Aug 10, 2018 · Currently, multiple imaging techniques are available to study the parotid region, such as US, CT, and MRI. However, it is still a challenge to ...
  24. [24]
    Magnetic resonance imaging of parotid gland tumors: a pictorial essay
    Nov 7, 2022 · Magnetic resonance imaging (MRI) is the imaging modality of choice for evaluation of suspected parotid gland lesions and differentiation ...
  25. [25]
    A systematic review and meta-analysis of the diagnostic ... - PubMed
    The clinical usefulness of fine-needle aspiration cytology (FNAC) for the diagnosis of parotid gland lesions is controversial. Many accuracy studies have been ...
  26. [26]
    Accuracy of Core Needle Biopsy Versus Fine Needle Aspiration ...
    Mar 12, 2015 · A systematic review and meta-analysis of the diagnostic accuracy of fine-needle aspiration cytology for parotid gland lesions. Am J Clin ...
  27. [27]
    The Diagnostic Value of Fine Needle Aspiration Biopsy in Parotid ...
    In the study, they reported 70% sensitivity, 93% specificity, 84% positive predictive value, 89% negative predictive value and 91% accuracy rate. They reported ...
  28. [28]
    Staging-major salivary glands - Pathology Outlines
    Jul 3, 2024 · Staging of definitive resections for primary salivary gland carcinoma and neuroendocrine carcinoma of the parotid, submandibular or ...
  29. [29]
    Sialolithiasis and Salivary Ductal Stenosis - RSNA Journals
    PURPOSE: To evaluate the accuracy of magnetic resonance (MR) sialography in detecting salivary glandular calculi and ductal stenoses.
  30. [30]
    Role of 18F-FDG PET/CT in Management of High-Grade Salivary ...
    Our results indicate that 18 F-FDG PET/CT provides superior diagnostic accuracy for evaluating the extent of tumors and for tumor staging, as compared with CT ...
  31. [31]
    Preoperative and Postoperative Electroneurographic Facial Nerve ...
    Electroneurography is a sensitive tool for monitoring clinically silent facial nerve function deficits in the context of preoperative tumor-induced damage.
  32. [32]
    Extracapsular Dissection vs Superficial Parotidectomy of Benign ...
    Sep 21, 2017 · Owing to recurrence rates as high as 45%, a push for more radical techniques took place. ... By the mid-20th century, superficial parotidectomy ( ...
  33. [33]
    Surgical management of benign tumors of the parotid gland - Frontiers
    This study compares our surgical experience with extracapsular dissection gland-sparing surgery (ECD) to traditional superficial parotidectomy in 56 patients.
  34. [34]
    Salivary Gland Center - Head and Neck Surgery
    Our multidisciplinary team of salivary gland specialists, radiation oncologists, and head and neck surgeons, all work together to provide you with ...
  35. [35]
    Outcome of Facial Nerve Integrity After Parotid Gland Surgery With ...
    Feb 11, 2025 · Outcome of facial nerve integrity after parotid gland surgery with and without intraoperative monitoring: a ten-year retrospective study.Missing: steroids | Show results with:steroids
  36. [36]
    Parotidectomy with Facial Nerve Dissection
    May 12, 2017 · Indications. Parotid neoplasm: The presence of an unexplained mass in the parotid gland warrants consideration for parotidectomy to be done both ...Missing: criteria | Show results with:criteria
  37. [37]
    [PDF] Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery
    Preoperative-dose timing. The optimal time for admin- istration of preoperative doses is within 60 minutes before surgical incision. This is a more-specific ...Missing: nerve | Show results with:nerve<|separator|>
  38. [38]
    Does the use of steroids perioperatively in parotid surgery affect ...
    May 8, 2018 · Best Practice. There is insufficient evidence to support the use of perioperative steroids in patients undergoing parotid surgery.Missing: swelling | Show results with:swelling
  39. [39]
    Enhanced Recovery After Surgery Nutrition Protocol for Major Head ...
    Jun 18, 2021 · Twenty-five patients were enrolled. Preoperatively, 40% of patients were malnourished, and 100% complied with perioperative nutrition ...
  40. [40]
    [PDF] Intraoperative monitoring of the facial nerve in parotid surgery
    The purpose of this article is to analyse the facial nerve electrophysiological monitoring effective ness in preventing injuries of this nerve during ...
  41. [41]
    Microsurgical dissection of facial nerve in parotidectomy
    Results: Our data showed no permanent injury to the facial nerve, and 17% of neuroapraxia that had resolved with time. Post-operative complications have ...Missing: early mortality
  42. [42]
    Parotidectomy (Parotid Gland Surgery) - Johns Hopkins Medicine
    A parotidectomy is surgery to remove part or all of a tumor (benign or cancerous) in the mouth's parotid gland.What Is The Parotid Gland? · Complications Of A... · Frequently Asked QuestionsMissing: definition | Show results with:definition
  43. [43]
    Surgical site infections after parotidectomy: management and ... - NIH
    Perioperative antibiotic treatment is recommended for patients undergoing parotid gland surgery and intravenous antibiotics during the post-operative course are ...
  44. [44]
    Jackson-Pratt Drain | Johns Hopkins Medicine
    Parotidectomy (parotid gland surgery); Laryngectomy. A graphic showing how a ... JP Drain Removal. When the output of each drain is less than 25 ...Why Might I Need A Jp Drain? · Caring For A Jp Drain · Emptying The Drain
  45. [45]
    Lagophthalmos - StatPearls - NCBI Bookshelf - NIH
    Taping of the eyelids at night can offer additional ocular surface protection without resorting to surgery.[8] There are also moisture chamber-type glasses ...
  46. [46]
    Incidence of Venous Thromboembolism in Otolaryngology–Head ...
    The primary means of preventing VTE is providing patients with adequate prophylaxis. This includes the use of mechanical strategies, such as early ambulation ...
  47. [47]
    [PDF] Parotid Gland Excision Post-Operative Instructions
    You usually need a night in the hospital following the surgery. It is unlikely to be very sore but regular painkillers will be arranged for you. There is ...Missing: guidelines | Show results with:guidelines
  48. [48]
    Minor Parotidectomy Complications: A Systematic Review - PubMed
    Jul 17, 2020 · Results: The pooled incidence of minor complications reported were hematoma 2.9% (95% confidence interval [CI]: 2.4-3.5), wound infection 2.3% ( ...Missing: facial nerve
  49. [49]
    Treatment of complications of parotid gland surgery - PMC - NIH
    The commonest complications after parotidectomy are temporary or permanent facial palsy and Frey's syndrome.Missing: preoperative | Show results with:preoperative
  50. [50]
    Parotid Duct Injuries Treatment & Management - Medscape Reference
    Sep 26, 2023 · Sialocele and salivary fistula can frequently be managed nonoperatively with antibiotics, pressure dressings, and serial aspiration.
  51. [51]
    Incidence of postoperative facial weakness in parotid tumor surgery
    Dec 26, 2019 · According to previous studies, 14 to 64% for temporary and 0 to 9% for permanent facial nerve weakness have been reported following ...
  52. [52]
    The risk of facial nerve palsy after benign parotidectomy. A quality ...
    Apr 18, 2024 · Recent studies have reported that temporary and permanent facial nerve palsy occurs in 18–27% and 0–6% of the patients, respectively [4–7].Missing: paresis | Show results with:paresis
  53. [53]
    The Management of Salivary Fistulas - PMC - NIH
    In the case of a parotid sialocele, conservative management is recommended as first-line therapy. This includes the use of pressure dressings, aspiration, ...
  54. [54]
    A Pilot Study Evaluating the Treatment of Postparotidectomy ...
    Our findings suggest that botulinum toxin type A offers a highly effective, safe, and noninvasive method of treatment in postparotidectomy sialocele.
  55. [55]
    Optimizing Airway Management Strategies for Anterior Neck ...
    May 25, 2025 · Bleeding and hematomas after parotidectomy are uncommon and are usually related to inadequate hemostasis at the time of the surgical procedure, ...
  56. [56]
    Massive sialadenitis resulting in critical airway after elective ...
    Jun 3, 2016 · Due to severe neck swelling, the patient developed critical airway compromise ... Its estimated incidence is 1 in 1000–3000 of all surgical cases.
  57. [57]
    Frey Syndrome - StatPearls - NCBI Bookshelf - NIH
    Jan 12, 2023 · ... auriculotemporal nerve. The auriculotemporal nerve, a branch of the trigeminal nerve, consists of parasympathetic fibers that signal the parotid ...
  58. [58]
    The incidence of Frey syndrome and treatment with botulinum toxin ...
    Oct 18, 2022 · The incidence of treatment‐demanding FS after parotid gland surgery between the years 2015–2020 was 2.6% in the Central Denmark Region.
  59. [59]
    Optimizing the Aesthetic Result of Parotidectomy with a Facelift ... - NIH
    Feb 8, 2019 · Parotid gland resection results in cheek volume loss leading to facial asymmetry. Multiple methods have been described to fill the parotidectomy ...
  60. [60]
    Autologous Fat Transfer: An Aesthetic and Functional Refinement for ...
    Parotidectomy is a surgical procedure associated to functional (Frey's syndrome) as well as aesthetic (facial asymmetry) complications that can be very ...
  61. [61]
    First bite syndrome: a complication of surgery involving ... - PubMed
    First bite syndrome (FBS) is the development of pain in the parotid region after the first bite of each meal and can be seen after surgery of the ...
  62. [62]
    First Bite Syndrome After Parotidectomy: A Case Series and Review ...
    Dec 14, 2020 · First bite syndrome (FBS) is a rare but potentially debilitating complication observed after surgery involving the upper cervical region.
  63. [63]
    Botulinum toxin A for the treatment of first bite syndrome—a ...
    First bite syndrome (FBS) is a rare, often temporary, postoperative pain syndrome that is characterized by pain in the parotid region with the first bite of a ...
  64. [64]
    Sensation loss after superficial parotidectomy: A prospective ...
    The purpose of this study was to evaluate the occurrence of hypoesthesia after superficial parotidectomy depending on preservation of posterior branch of the ...
  65. [65]
    Preservation of the great auricular nerve during parotidectomy
    The area of sensory loss decreased in an exponential fashion in both groups. The majority of the change occurred within 6 months. We conclude that preservation ...
  66. [66]
    Why Do Parotid Pleomorphic Adenomas Recur? A Systematic ... - NIH
    May 15, 2017 · ... recurrence rate, and malignant transformation. ... [Recurrent benign tumors of the parotid gland and their tendency for becoming malignant].
  67. [67]
    Outcomes and prognostic factors in parotid gland malignancies - NIH
    Twenty‐nine patients (14.5%) experienced recurrences, with mean time to recurrence of 23.6 months (range: 1‐82 months). Five‐ and 10‐year OS were 81% and 73%, ...
  68. [68]
    Recurrent Pleomorphic Adenoma of the Parotid Gland in Pediatric ...
    Overall, the recurrence rate was estimated to be between 8% and 45% after enucleation, between 2% and 5% after superficial parotidectomy, and less than 0.4% ...Missing: cure | Show results with:cure
  69. [69]
    Systematic Review and Case Report on the Surgical Management ...
    Recurrence rates were 3.27% after extracapsular dissection (ED), 0.73% after partial superficial parotidectomy (PSP), and 2.41% after superficial parotidectomy ...
  70. [70]
    Long‐term follow‐up and prognostic analysis of parotid tumors in ...
    Jun 4, 2024 · The 5-year overall survival (OS) and 5-year locoregional recurrence-free survival (LRFS) rates for benign tumors were 100.0% and 92.9%, ...Missing: cure | Show results with:cure
  71. [71]
    Malignant Parotid Tumors: Practice Essentials, Anatomy, Diagnosis
    Jul 6, 2023 · For patients with low-grade tumors without nodal or distant metastasis, 5-year survival is 75-95%, whereas patients with high-grade tumors ...
  72. [72]
    Benefit of Adjuvant Radiotherapy in Parotid Cancer: Single Center ...
    Conclusions: Patients with parotid cancer who received adjuvant radiotherapy had a local control of 92% at two years. The factors identified with worst local ...
  73. [73]
    Patient safety and quality improvements in parotid surgery - PMC - NIH
    The specific procedure used varies based on several tumor and patient factors. Common complications after parotidectomy include facial nerve paresis, recurrence ...Discussion · Intraoperative... · Postoperative ConsiderationsMissing: acute | Show results with:acute
  74. [74]
    Long‐Term Facial Nerve Outcome in Primary Parotid Cancer ...
    May 29, 2021 · The rate of permanent postoperative facial nerve dysfunction after benign tumor surgery ranges between 1% and 6%. ... In general, the risk is ...Baseline, Tumor, And Therapy... · Facial Nerve Function · Discussion<|control11|><|separator|>
  75. [75]
    Long-term outcomes and quality of life following parotidectomy for ...
    The overall reported complication rate of parotidectomy is 21.6%. Complications such as postoperative numbness, Frey's syndrome, pain, mouth dryness and scar- ...Missing: acute | Show results with:acute
  76. [76]
    Meta-analysis of surgical approaches to the treatment of parotid ...
    Six studies show a low recurrence rate (0.02, 95% CI = 0.01–0.04) after limited parotidectomy. Six studies demonstrate a low recurrence rate (0.01, 95% CI = ...Missing: cure | Show results with:cure
  77. [77]
    Evaluation of the effectiveness of superficial parotidectomy and ...
    Dec 22, 2023 · Moreover, PSP does not affect the completeness of surgical resection, and the tumour recurrence rate is not significantly higher. The results of ...
  78. [78]
    Malignant Salivary Gland Tumors - StatPearls - NCBI Bookshelf - NIH
    [235] All salivary gland malignancies require post-treatment surveillance for up to 20 years (especially AdCC due to its propensity for delayed recurrences ...
  79. [79]
    Management of Salivary Gland Malignancy: ASCO Guideline
    Apr 26, 2021 · Salivary gland malignancies (SGMs) are rare neoplasms accounting for < 1%-5% of all head and neck cancers. Given the rarity of the disease, ...
  80. [80]
    Follow-up after treatment for salivary gland cancer
    The chance that salivary gland cancer will come back (recur) is greatest within 2 years, so you will need close follow-up during this time.
  81. [81]
    Neuromuscular Reeducation in Facial Palsy - Physiopedia
    Neuromuscular facial re-education (NMR) is one treatment that has been shown to be effective in encouraging the recovery of symmetrical movement in the face.
  82. [82]
    Paresis - an introduction and exercises - Facial Palsy UK
    Jan 5, 2019 · Video explaining what to do during the Paresis stage of facial paralysis. This is likely to be at least three months after diagnosis and when the face is no ...
  83. [83]
    PAROTID Definition & Meaning - Merriam-Webster
    Word History. Etymology. New Latin parotid-, parotis parotid gland, from Latin, tumor near the ear, from Greek parōtid-, parōtis, from para- + ōt-, ous ear ...
  84. [84]
    parotid gland - Wiktionary, the free dictionary
    From Ancient Greek παρωτίς (parōtís, “(gland) behind the ear”), from παρά (pará, “behind”) + οὖς (oûs, “ear”). Noun. parotid gland (plural parotid glands).
  85. [85]
    parotidectomy, n. meanings, etymology and more | Oxford English ...
    The earliest known use of the noun parotidectomy is in the 1890s. OED's earliest evidence for parotidectomy is from 1893, in a dictionary by R. J. Dunglison.Missing: origin | Show results with:origin
  86. [86]
    parotitis - Wiktionary, the free dictionary
    Etymology. Learned borrowing from Ancient Greek παρωτῖτις (parōtîtis, “(disease of the) parotid gland”), from παρωτίς (parōtís, “gland behind the ear”). By ...
  87. [87]
    parotitis, n. meanings, etymology and more | Oxford English Dictionary
    The earliest known use of the noun parotitis is in the late 1700s. OED's earliest evidence for parotitis is from 1796, in the writing of Erasmus Darwin, ...
  88. [88]
    [PDF] Classification of parotidectomies: a proposal of the European ...
    Feb 1, 2016 · We propose to use only two terms to define the parotid surgery: extracapsular dissection and parotidectomy. (Table 4). The term extracapsular ...Missing: HNS | Show results with:HNS
  89. [89]
    Surgery of the parotid gland: Evolution of techniques, nomenclature ...
    Aug 9, 2025 · This chapter describes the origins of parotid surgery and its evolution to date. A step-by-step explanation of extracapsular dissection is ...<|control11|><|separator|>
  90. [90]
    [PDF] Clinical Indicators: Parotidectomy
    The AAO-HNS/F emphasizes that these clinical indicators should not be deemed inclusive of all proper treatment decisions or methods of care, nor exclusive of ...
  91. [91]
    Radical Resection of Malignant Tumors of Major Salivary Glands - NIH
    Feb 6, 2024 · According to the classic rule, radical resection of a head and neck tumor requires clean margins of at least 5 mm, although recent studies have ...
  92. [92]
    Neck Dissection Classification Update: Revisions Proposed by the ...
    Standardize neck dissection terminology using a system that was logical, straightforward, and easy to remember.<|control11|><|separator|>